Company intelligence / Profile preview
Life Science Pharmaceuticals
- Ownership
- Private
- Development stage
- Phase 2
Overview
Life Science Pharmaceuticals has a portfolio of pre-clinical and clinical assets targeting cancer, diabetes, and other serious diseases. Past clinical assets include sibrotuzumab (FAP antagonist, discontinued for colorectal cancer) and monoclonal antibody 806 (EGFR epitope, out-licensed to AbbVie, still in clinical development)[1][6]. Another asset, KW2871 targeting ganglioside GD3, was studied in metastatic melanoma (Phase 2, completed)[6]. No marketed products.
- Therapeutic areas
- OtherOncologyEndocrinology
- Modalities
- Monoclonal antibodySmall molecule
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on Life Science Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Life Science Pharmaceuticals.